Se connecter Inscription gratuite

Akari Therapeutics Plc BPA estimée Q/Q

Quel est le BPA estimée Q/Q de Akari Therapeutics Plc?

Le BPA estimée Q/Q de Akari Therapeutics Plc est -100.00%

Quelle est la définition de BPA estimée Q/Q?



Le taux de croissance prospectif du BPA trimestriel, d'une année à l'autre , correspond à l'augmentation estimée du BPA d'une entreprise pour le prochain trimestre par rapport à la performance d'un trimestre précédent.

The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

BPA estimée Q/Q des entreprises dans Health Care secteur sur NASDAQ par rapport à Akari Therapeutics Plc

Que fait Akari Therapeutics Plc?

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.

Entreprises avec bpa estimée q/q similaire à Akari Therapeutics Plc